N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.
N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.
复制标题
DOI：
10.3389/fphar.2014.00070
复制
发表时间：
2014
影响因子：
5.6
通讯作者：
Koya D
中科院分区：
文献类型：
--
作者：
Kanasaki K;Nagai T;Nitta K;Kitada M;Koya D
在发达国家，45%的死亡是由纤维增生性疾病造成的。治疗器官纤维化对纤维增生性疾病至关重要。糖尿病肾病是一种常见的肾脏纤维增生性疾病，与多器官功能障碍有关。然而，治疗糖尿病肾病的方法尚未建立。在这篇综述中，我们讨论了新的治疗糖尿病肾纤维化的可能性，重点是内源性抗纤维化肽，n-乙酰-seryl-天冬氨酸-赖氨酸-脯氨酸（AcSDKP），它是血管紧张素转换酶的底物，在各种纤维化疾病的实验模型中显示出有意义的抗纤维化作用。
Fibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to combat diabetic nephropathy has not yet been established. In this review, we discuss the novel therapeutic possibilities for kidney fibrosis in diabetes focusing on the endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is the substrate for angiotensin-converting enzyme and exhibits meaningful anti-fibrotic effects in various experimental models of fibrotic disease.